Cargando…

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2

Detalles Bibliográficos
Autores principales:	Wang, M. L., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Flinn, I. W., Miklos, D. B., Pagel, J. M., Kersten, M. J., Houot, R., Beitinjaneh, A., Peng, W., Fang, X., Shen, R. R., Siddiqi, R., Kloos, I., Reagan, P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430665/ http://dx.doi.org/10.1097/01.HS9.0000847336.10486.b2

Ejemplares similares

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
por: Wang, Michael, et al.
Publicado: (2023)

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
por: Locke, Frederick L., et al.
Publicado: (2017)

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Wayne, Alan S., et al.
Publicado: (2022)

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023)

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
por: Shah, Bijal D., et al.
Publicado: (2022)

KTeV startup and status
por: Kessler, R S
Publicado: (1996)

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2021)

The KTeV hardware cluster counter
por: Bown, C, et al.
Publicado: (1995)

The KTeV CsI calorimeter
por: Roodman, A
Publicado: (1996)

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
por: Jain, Michael D., et al.
Publicado: (2023)

Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials
por: Westin, Jason R., et al.
Publicado: (2021)

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
por: Wang, Michael, et al.
Publicado: (2020)

First result from KTeV on epsilon epsilon
por: Winstein, Bruce D
Publicado: (1999)

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
por: Ghione, Paola, et al.
Publicado: (2022)

Development and performance of the KTeV transition radiation detector system
por: Solomey, Nickolas
Publicado: (1998)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

New results in kaon physics from NA48 and KTeV
por: Wanke, Rainer
Publicado: (2003)

1117. A Retrospective Analysis of Paediatric Prescribing in British Columbia from 2013 to 2016
por: Saatchi, Ariana, et al.
Publicado: (2019)

1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients
por: Kalaria, Shamir N, et al.
Publicado: (2021)

$\epsilon'/\epsilon$ results from NA48 and KTeV E832
por: Vallage, B
Publicado: (2003)

1117 The Acute Febrile Illness Surveillance Study in Puerto Rico: Findings from the First Two Years
por: Tomashek, Kay M., et al.
Publicado: (2014)

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Flinn, Ian W., et al.
Publicado: (2023)

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
por: Shah, Bijal D., et al.
Publicado: (2022)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
por: Shah, Bijal, et al.
Publicado: (2023)

Non‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)
por: Altahan, Rahaf, et al.
Publicado: (2019)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
por: Westin, Jason, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

Lithospheric mantle buoyancy: the role of tectonic convergence and mantle composition
por: Boonma, K., et al.
Publicado: (2019)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

1117. Avascular Necrosis of the Femoral Head as a Sequela of Shiga Toxin-producing Escherichia coli (STEC) Infection
por: Stone-Garza, Kristi, et al.
Publicado: (2018)

Whole-mantle convection with tectonic plates preserves long-term global patterns of upper mantle geochemistry
por: Barry, T. L., et al.
Publicado: (2017)

Author Correction: Lithospheric mantle buoyancy: the role of tectonic convergence and mantle composition
por: Boonma, K., et al.
Publicado: (2020)

Zuma Modified Maneuver as a Treatment to Geotropic Lateral Semicircular Canal Benign Paroxysmal Positional Vertigo
por: Ramos, Bernardo Faria, et al.
Publicado: (2021)

The evolution of the Galápagos mantle plume
por: Soderman, Caroline R., et al.
Publicado: (2023)

P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
por: Oluwole, Olalekan, et al.
Publicado: (2023)

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
por: Perales, Miguel-Angel, et al.
Publicado: (2022)

PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING
por: Leslie, Lori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_11dh0lgsvn572mr41hg4jk421j